{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:09:34Z","timestamp":1788829774670,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T00:00:00Z","timestamp":1639267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Piperazine derivatives belong to the popular psychostimulating compounds from the group of designer drugs. They are an alternative to illegal drugs such as ecstasy and amphetamines. They are being searched by consumers for recreational use due to their stimulating and hallucinogenic effects. Many NPS-related poisonings and deaths have been reported where piperazines have been found. However, a major problem is the potential lack of laboratory confirmation of the involvement of piperazine derivatives in the occurrence of poisoning. Although many methods have been published, piperazine derivatives are not always included in a routine analytical approach or targeted toxicological analysis. There is an increasing need to provide qualitative evidence for the presence of piperazine derivatives and to ensure reproducible quantification. This article describes a new rapid method of detecting piperazine derivatives in biological material, using LC-MS. All target analytes were separated in a 15 min run time and identified based on the precursor ion, at least two product ions, and the retention time. Stable isotopically labeled (SIL) internal standards: BZP-D7, mCPP-D8 and TFMPP-D4 were used for analysis, obtaining the highest level of confidence in the results. The proposed detection method provides the analytical confirmation of poisoning with piperazine designer drugs.<\/jats:p>","DOI":"10.3390\/jcm10245813","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T01:29:33Z","timestamp":1639358973000},"page":"5813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4653-3497","authenticated-orcid":false,"given":"Anna","family":"Welz","sequence":"first","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-1443","authenticated-orcid":false,"given":"Marcin","family":"Koba","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-117X","authenticated-orcid":false,"given":"Piotr","family":"Ko\u015bli\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Si\u00f3dmiak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Faculty of Pharmacy, Collegium Medicum Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wadsworth, E., Drummond, C., and DeLuca, P. (2018). The Dynamic Environment of Crypto Markets: The Lifespan of New Psychoactive Substances (NPS) and Vendors Selling NPS. Brain Sci., 8.","DOI":"10.3390\/brainsci8030046"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Giorgetti, A., Pascali, J., Fais, P., Pelletti, G., Gabbin, A., Franchetti, G., Cecchetto, G., and Viel, G. (2021). Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. Life, 11.","DOI":"10.3390\/life11050440"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: Mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Var\u00ec, M.R., Mannocchi, G., Tittarelli, R., Campanozzi, L.L., Nittari, G., Feola, A., Ronchi, F.U., and Ricci, G. (2020). New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17228704"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0897190014544814","article-title":"Toxicology and Management of Novel Psychoactive Drugs","volume":"28","author":"Kersten","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugalcdep.2011.10.007","article-title":"Piperazine compounds as drugs of abuse","volume":"122","author":"Arbo","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2016.04.010","article-title":"Benzylpiperazine: \u201cA messy drug\u201d","volume":"164","author":"Katz","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejfs.2014.03.002","article-title":"Development of a targeted GC\/MS screening method and validation of an HPLC\/DAD quantification method for piperazines\u2013amphetamines mixtures in seized material","volume":"4","author":"Boumrah","year":"2014","journal-title":"Egyptian J. Forensic Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/THC-199008","article-title":"A novel analytical method of TFMPP and mCPP in fluids of drug addicts using LLE-GC\/NPD","volume":"27","author":"Ren","year":"2019","journal-title":"Technol. Health Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1007\/s00216-015-8660-z","article-title":"Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing","volume":"407","author":"Castaneto","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2478\/acph-2020-0035","article-title":"Piperazine derivatives as dangerous abused compounds","volume":"70","author":"Welz","year":"2020","journal-title":"Acta Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00204-016-1777-9","article-title":"In vitro hepatotoxicity of \u2018Legal X\u2019: The combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis","volume":"91","author":"Silva","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_13","first-page":"487","article-title":"Piperazine derivatives in designer drugs\u2013compounds of great popularity and high risk for human health","volume":"73","author":"Welz","year":"2017","journal-title":"Farm. Pol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"\u201c Not for Human Consumption\u201d: A Review of Emerging Designer Drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pharma.2008.04.001","article-title":"La 1-benzylpip\u00e9razine (BZP) et la 1-(3-trifluorom\u00e9thylph\u00e9nyl)pip\u00e9razine (TFMPP): \u00c9mergence de deux substances donnant lieu \u00e0 un usage abusif","volume":"66","author":"Lecompte","year":"2008","journal-title":"Ann. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugpo.2010.12.002","article-title":"BZP-party pills: A review of research on benzylpiperazine as a recreational drug","volume":"22","author":"Cohen","year":"2011","journal-title":"Int. J. Drug Policy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1556-4029.2010.01457.x","article-title":"Validation of an LC-MS Method for the Detection and Quantification of BZP and TFMPP and their Hydroxylated Metabolites in Human Plasma and its Application to the Pharmacokinetic Study of TFMPP in Humans*","volume":"55","author":"Antia","year":"2010","journal-title":"J. Forensic Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00213-015-4165-x","article-title":"Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: A single-dose study","volume":"233","author":"Lee","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1556-4029.2012.02254.x","article-title":"A Fatality Following Ingestion of the Designer Drug Meta-Chlorophenylpiperazine (mCPP) in an Asthmatic-HPLC-MS\/MS Detection in Biofluids and Hair","volume":"58","author":"Gaillard","year":"2012","journal-title":"J. Forensic Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(01)00146-6","article-title":"The subjective effects of MDMA and mCPP in moderate MDMA users","volume":"65","author":"Tancer","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ijnp\/pyy047","article-title":"Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics","volume":"21","author":"Luethi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jms.556","article-title":"New designer drug 1-(3,4-methylenedioxybenzyl) piperazine(MDBP): Studies on its metabolism and toxicological detection in rat urine using gas chromatography\/mass spectrometry","volume":"39","author":"Staack","year":"2004","journal-title":"J. Mass Spectrom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF03161209","article-title":"Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP)","volume":"4","author":"Wood","year":"2008","journal-title":"J. Med. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2017.10.022","article-title":"Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data","volume":"182","author":"Hondebrink","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2045125320967197","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: A review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1178646919873925","DOI":"10.1177\/1178646919873925","article-title":"Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions","volume":"12","author":"Scotton","year":"2019","journal-title":"Int. J. Tryptophan Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Parrott, A.C. (2018). Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs. Brain Sci., 8.","DOI":"10.3390\/brainsci8030043"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00216-012-6548-8","article-title":"Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS\/MS analysis","volume":"405","author":"Swortwood","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fpsyt.2017.00240","article-title":"The \u201cEndless Trip\u201d among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review","volume":"8","author":"Orsolini","year":"2017","journal-title":"Front. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/jat\/bkx090","article-title":"Stability of Synthetic Piperazines in Human Whole Blood","volume":"42","author":"Lau","year":"2017","journal-title":"J. Anal. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/dta.307","article-title":"Current awareness of piperazines: Pharmacology and toxicology","volume":"3","author":"Elliott","year":"2011","journal-title":"Drug Test. Anal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7861\/clinmedicine.14-4-409","article-title":"\u2018Designer drugs\u2019: Update on the management of novel psychoactive substance misuse in the acute care setting","volume":"14","author":"Smith","year":"2014","journal-title":"Clin. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-017-4764-9","article-title":"The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers","volume":"235","author":"Thomas","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bcp.2014.01.024","article-title":"Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives","volume":"88","author":"Simmler","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.tiv.2015.04.001","article-title":"Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models","volume":"29","author":"Arbo","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.toxlet.2014.06.031","article-title":"Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment","volume":"229","author":"Arbo","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yjmcc.2019.09.007","article-title":"Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings","volume":"136","author":"Zwartsen","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12640-016-9604-x","article-title":"An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse","volume":"29","author":"Persona","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuro.2018.03.007","article-title":"Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA)","volume":"66","author":"Zwartsen","year":"2018","journal-title":"NeuroToxicology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF00558281","article-title":"Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts","volume":"6","author":"Campbell","year":"1973","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/15563650.2011.572076","article-title":"The clinical toxicology of the designer \u201cparty pills\u201d benzylpiperazine and trifluoromethylphenylpiperazine","volume":"49","author":"Schep","year":"2011","journal-title":"Clin. Toxicol."},{"key":"ref_42","first-page":"114","article-title":"Surveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tools","volume":"21","author":"Tang","year":"2015","journal-title":"Hong Kong Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12024-019-00209-z","article-title":"Detection and quantification of synthetic cathinones and selected piperazines in hair by LC-MS\/MS","volume":"16","author":"Niebel","year":"2019","journal-title":"Forensic Sci. Med. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00216-009-3394-4","article-title":"LC-MS\/MS screening method for designer amphetamines, tryptamines, and piperazines in serum","volume":"396","author":"Wohlfarth","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chroma.2015.04.002","article-title":"Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography\u2013high resolution mass spectrometry and library matching","volume":"1397","author":"Concheiro","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1007\/s00216-014-7825-5","article-title":"Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC-HR-QTOFMS approach","volume":"406","author":"Paul","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jms.3115","article-title":"Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS\/MS using neutral loss and precursor ion scan","volume":"48","author":"Montesano","year":"2013","journal-title":"J. Mass Spectrom."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jat\/34.8.464","article-title":"Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples","volume":"34","author":"Dickson","year":"2010","journal-title":"J. Anal. Toxicol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.32383\/farmpol\/124913","article-title":"Coronavirus\u2013current medical and social problem","volume":"76","author":"Welz","year":"2020","journal-title":"Farm. Pol."},{"key":"ref_50","unstructured":"(2021). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Trends and Developments, MDMA, New psychoactive substances. Eur. Drug Rep., Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13838\/TDAT21001ENN.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15935","DOI":"10.1038\/s41598-018-34376-w","article-title":"Heat-induced bone diagenesis probed by vibrational spectroscopy","volume":"8","author":"Marques","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Scientific Working Group for Forensic Toxicology (2013). Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology. J. Anal. Toxicol., 37, 452\u2013474.","DOI":"10.1093\/jat\/bkt054"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/rcm.895","article-title":"Quantitative characterization of differential ion suppression on liquid chromatography\/atmospheric pressure ionization mass spectrometric bioanalytical methods","volume":"17","author":"Avery","year":"2002","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/rcm.1790","article-title":"Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography\/mass spectrometry: Necessity or not?","volume":"19","author":"Stokvis","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC\u2013MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4155\/bio-2017-0059","article-title":"Matrix effect management in liquid chromatography mass spectrometry: The internal standard normalized matrix effect","volume":"9","year":"2017","journal-title":"Bioanalysis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1515\/CCLM.2004.250","article-title":"Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and\/or doping control","volume":"42","author":"Maurer","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.sbsr.2016.12.001","article-title":"Extending the capability of forensic electrochemistry to the novel psychoactive substance benzylpiperazine","volume":"13","author":"Waddell","year":"2017","journal-title":"Sens. Bio-Sens. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.forsciint.2011.08.005","article-title":"Microcrystalline identification of selected designer drugs","volume":"214","author":"Elie","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1039\/c3ay40511g","article-title":"Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials","volume":"5","author":"Philp","year":"2013","journal-title":"Anal. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.talanta.2013.08.029","article-title":"Chemiluminescence detection of piperazine designer drugs and related compounds using tris(2,2\u2032-bipyridine)ruthenium(III)","volume":"116","author":"Waite","year":"2013","journal-title":"Talanta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1520\/JFS2004239","article-title":"Simultaneous Separation of Different Types of Amphetamine and Piperazine Designer Drugs by Capillary Electrophoresis with a Chiral Selector","volume":"50","author":"Bishop","year":"2005","journal-title":"J. Forensic Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:03Z","timestamp":1760168763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,12]]},"references-count":62,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10245813"],"URL":"https:\/\/doi.org\/10.3390\/jcm10245813","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,12]]}}}